scispace - formally typeset
M

Mirella Marino

Researcher at Università Campus Bio-Medico

Publications -  109
Citations -  9962

Mirella Marino is an academic researcher from Università Campus Bio-Medico. The author has contributed to research in topics: Thymoma & Thymic carcinoma. The author has an hindex of 32, co-authored 101 publications receiving 6878 citations. Previous affiliations of Mirella Marino include Sapienza University of Rome & Catholic University of the Sacred Heart.

Papers
More filters
Journal ArticleDOI

Circulating miR-21-5p and miR-148a-3p as emerging non-invasive biomarkers in thymic epithelial tumors.

TL;DR: This pilot study suggests that circulatingmiR-21-5p and miR-148a-3p could represent novel non-invasive biomarkers to evaluate the efficacy of therapy and the prognosis of TET.
Journal ArticleDOI

Thymic Epithelial Tumors phenotype relies on miR-145-5p epigenetic regulation.

TL;DR: The results suggest that the epigenetic regulation of miR-145-5p expression, as well as the modulation of its functional targets, could be relevant players in tumor progression and treatment response in TETs.
Journal ArticleDOI

Dataset for reporting of thymic epithelial tumours: recommendations from the International Collaboration on Cancer Reporting (ICCR)

TL;DR: The International Collaboration on Cancer Reporting (ICCR) is a not‐for‐profit organization formed by the Royal Colleges of Pathologists of Australasia and the United Kingdom, the College of American Pathologists, the Canadian Association of Pathologist–Association Canadienne des Pathologists in association with the Canadian Partnership Against Cancer, and the European Society of Pathology.
Journal ArticleDOI

Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study

TL;DR: The data suggest that miR-22 is of potential interest as non-invasive biomarker to predict clinical outcome in DLBCL patients and can pave the way to the development of targeted therapy approaches for specific subgroups of DLBCl patients.